secwatch.observer — SEC 8-K summary
======================================

Issuer:     Syros Pharmaceuticals, Inc. (—)
CIK:        0001556263
Form:       8-K
Filed at:   2023-10-02T23:59:59+00:00
Accession:  0001193125-23-248476
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.05, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Syros restructures with 35% staff cut; CEO Simonian retiring, Chee named successor
--------------------------------------------------------------------------------

- Company ends SY-2101 APL program and all preclinical/discovery; focuses on tamibarotene for MDS/AML.
- Workforce cut ~35%; expects $1.8-2.0M severance costs and $0.3-0.6M asset impairment in Q3 2023.
- CEO Nancy Simonian retiring Dec 1; Conley Chee (CCO/CBO) appointed President & CEO effective Dec 2.
- CSO Eric Olson departs Oct 16; receives $382,200 severance and accelerated vesting of 40,666 RSUs.
- Board member Mark Alles resigned Sept 30; no disagreement cited.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1556263/000119312523248476/0001193125-23-248476-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1556263/000119312523248476/d486037d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-248476

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer